News	Events
Publications	Companies
Clinical Trials

Monthly Archives: March 2005

• LNA inhibits siRNA-mediated induction of interferon.

  0 Replies
  

  March 10, 2005

  Copenhagen, 10th March 2005  Santaris Pharma, the Danish biopharmaceutical company developing innovative gene-targeting drugs for the treatment of cancer, announces the publication of a study showing that its Locked Nucleic Acid (LNA) technology, when incorporated into siRNAs, can inhibit side effects such as interferon induction without compromising their gene inhibiting... Contine Reading & Discuss→